GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics techn…
| Métrica | SIGHT.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -1054.2% | -34.4% | -1019.8% |
| Net Margin | -933.4% | -32.5% | -900.9% |
| FCF Margin | -862.5% | -12.6% | -849.9% |
| ROE | — | -39.2% | — |
| ROA | -130.2% | -30.9% | -99.2% |
| Current Ratio | 0.24 | 2.73 | -2.49 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -130.2% | — |
| ✗Flujo de caja operativo positivo | −€13M | −€25M |
| ✓Rentabilidad sobre activos al alza | -130.2% | -287.1% |
| ✓Caja operativa/activos supera al ROA | -120.3% | ROA -130.2% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 0.24 | 0.26 |
| ✗Sin aumentar el nº de acciones | — | 49M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.14 | 0.14 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -862.5% |
| ✓ROCE > 10 % | 133.3% |
| ✗Ventas > 5 %/año (3 años) | -34.2% |
| ✓Deuda neta/EBITDA < 3x | -0.3x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 824.6% |
GENSIGHT BIOLOGICS cotiza a 0.07 EUR y tiene una capitalización bursátil de €18M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud